The safety of antiemetic medications for the prevention of chemotherapy-induced nausea and vomiting

References

• Bloechl-Daum B, Deuson RR, Mavros P, et al. Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol. 2006;24:4472–4478.
   PubMed Web of Science ®Google Scholar
• Cohen L, de Moor CA, Eisenberg P, et al. Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer. 2007;15(5):497–503.
   PubMed Web of Science ®Google Scholar
• Navari RM. Management of chemotherapy-induced nausea and vomiting: focus on newer agents and new uses for older agents. Drugs. 2013;73:249–262.
   PubMed Web of Science ®Google Scholar
• Navari RM. Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer. Future Oncol. 2010;6:1073–1084.
   PubMed Web of Science ®Google Scholar
• Curran MP, Robinson DM. Aprepitant: a review of its use in the prevention of nausea and vomiting. Drugs. 2009;69:1853–1858.
   PubMed Web of Science ®Google Scholar
• Aapro M, Carides A, Rapoport BL, et al. Aprepitant and fosaprepitant: a 10-year review of efficacy and safety. Oncologist. 2015;20:450–458.
   PubMed Web of Science ®Google Scholar
• Navari RM. Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV). Drug Des Devel Ther. 2015;9:155–161.
   PubMed Web of Science ®Google Scholar
• Navari RM. Rolapitant for the treatment of chemotherapy induced nausea and vomiting. Expert Rev Anticancer Therapy. 2015;15:1127–1133.
   PubMed Web of Science ®Google Scholar
• Navari RM, Einhorn LH, Loehrer PJ, et al. A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study. Support Care Cancer. 2007;15:1285–1291.
   PubMed Web of Science ®Google Scholar
• Tan L, Liu J, Liu X, et al. Clinical research of olanzapine for the prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res. 2009;28:1–7.
   PubMed Web of Science ®Google Scholar
• Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol. 2011;9:188–195.
   PubMedGoogle Scholar
• Navari RM. Treatment of chemotherapy-induced nausea. Community Oncol. 2012;9:20–26.
   Google Scholar
• Stern RM, Koch KL, Andrews PLR, editors. Nausea: mechanisms and management. New York (NY): Oxford University Press; 2011.
   Google Scholar
• Koga T, Fukuda H. Neurons in the nucleus of the solitary tract mediating inputs from vagal afferents and the area postrema in the pattern generator in the emetic act in dogs. Neurosci Res. 1992;14:366–379.
   Web of Science ®Google Scholar
• Yates BJ, Grelot L, Kerman IA, et al. Organization of the vestibular inputs to nucleus tractus solitarius and adjacent structures in cat brain stem. Am J Physiol. 1994;267:R974–R983.
   PubMed Web of Science ®Google Scholar
• Roila F, Herrstedt J, Aapro M, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol. 2010;21:232–243.
   PubMed Web of Science ®Google Scholar
• Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2011;29:4189–4198.
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Bohike K, Lyman GH, et al. Antiemetics: American Society of Clinical Oncology focused guideline update. J Clin Oncol. 2015. doi:JCO2015.64.3635.
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology version 1 2015. Antiemesis. National Comprehensive Cancer Network (NCCN) [Internet]. [cited 2015 Oct]. Available from: http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf
   Google Scholar
• Navari RM. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting: two new agents. J Support Oncol. 2003;1:89–103.
   PubMedGoogle Scholar
• Simpson K, Spencer CM, McClellan KJ. Tropisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs. 2000;59:1297–1315.
   PubMed Web of Science ®Google Scholar
• Kimura E, Niimi S, Watanabe A, et al. [Study on clinical effect of a continuous intravenous infusion of azasetron against nausea and vomiting induced by anticancer drugs including CDDP]. Gan To Kagaku Ryoho. 1996;23:477–481.
   PubMedGoogle Scholar
• Taguchi T, Tsukamoto F, Watanabe T, et al. [Usefulness of ramosetron hydrochloride on nausea and vomiting in CMF or CEF therapy for breast cancer]. Gan To Kagaku Ryoho. 1999;26:1163–1170.
   PubMedGoogle Scholar
• Hesketh PJ. Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. Cancer Invest. 2000;18:163–173.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Dolasetron mesylate and serious cardiovascular reactions. WHO Drug Inf. 2006;20(3):185.
   Google Scholar
• U.S. Food and Drug Information. FDA drug safety communication: abnormal heart rhythms associated with use of anzemet (dolasetron mesylate) [Internet]. [cited 2015 Nov 9]. Available from: http://www.fda.gov/Drugs.DrugSafety/usm237081.htm
   Google Scholar
• Ondansetron [Internet]. [cited 2015 Nov 9]. Available from: www.drugs.com/fda/ondansetron
   Google Scholar
• Mason JW, Moon TE, O’Boyle E, et al. A randomized, placebo-controlled, four-period cross-over definitive QT study of the effects of APF530 exposure, high-dose intravenous granisetron, and moxifloxacin on QTC prolongation. Cancer Manage Res. 2014;6:183–189.
   Google Scholar
• Boccia RV, Gordan LN, Clark G, et al. Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study. Support Care Cancer. 2011;19:1609–1617.
   PubMed Web of Science ®Google Scholar
• Raftopoulos H, Cooper W, O’Boyle E, et al. Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trial. Support Care Cancer. 2015;23:723–732.
   PubMed Web of Science ®Google Scholar
• Navari RM. The current status of the use of palonosetron. Expert Opin Pharmacother. 2013;14:1281–1284.
   PubMed Web of Science ®Google Scholar
• Navari RM. Palonosetron for the treatment of chemotherapy-induced nausea and vomiting. Expert Opin Pharmacother. 2014;15:2599–2608.
   PubMed Web of Science ®Google Scholar
• Eisenberg P, MacKintosh FR, Ritch P, et al. Efficacy, safety, and pharmacokinetics of palonosetron in patients receiving highly emetogenic, cisplatin-based chemotherapy: a dose-ranging, clinical study. Ann Oncol. 2004;15:330–337.
   PubMed Web of Science ®Google Scholar
• Rojas C, Thomas AG, Alt J, et al. Palonosetron triggers 5-HT3 receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol. 2010;626:193–199.
   PubMed Web of Science ®Google Scholar
• Botrel T, Clark O, Clark L, et al. Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis. Support Care Cancer. 2011;19:823–832.
   PubMed Web of Science ®Google Scholar
• Schwartzberg L, Barbour SY, Morrow GR, et al. Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV). Support Care Cancer. 2014;22:469–477.
   PubMed Web of Science ®Google Scholar
• Popovic M, Warr DG, DeAngelis C, et al. Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials. Support Care Cancer. 2014;22:1485–1497.
   PubMed Web of Science ®Google Scholar
• Yavas C, Dogan U, Yavas G, et al. Acute effect of palonosetron on electrocardiographic parameters in cancer patients: a prospective study. Support Care Cancer. 2012;20:2343–2347.
   PubMed Web of Science ®Google Scholar
• Aogi K, Sakai H, Yoshizawa H, et al. A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy. Support Care Cancer. 2012;20:1507–1514.
   PubMed Web of Science ®Google Scholar
• Roila F, Ballatori E, Ruggeri B, et al. Aprepitant versus metoclopramide, both combined with dexamethasone, for the preventing cisplatin-induced delayed emesis: a randomized, double-blind study. J Clin Oncol. 2014;32:5s. (Suppl; abstr 9503)
   PubMed Web of Science ®Google Scholar
• Navari RM, Nagy CK, Gray SE. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer. 2013;21:1655–1663.
   PubMed Web of Science ®Google Scholar
• European Medicine Agency Metoclopramide use recommendations. 2013 Jul 26 [cited 2015 Nov 9]. Available from: www.ema.europa.eu.
   Google Scholar
• Diemunsch P, Grelot L. Potential of substance P antagonists as antiemetics. Drugs. 2000;60:533–546.
   PubMed Web of Science ®Google Scholar
• Sankhala KK, Pandya DM, Sarantopoulos J, et al. Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant. Expert Opin Drug Metab Toxicol. 2009;5:1607–1614.
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Grunberg SM, Herrstedt J, et al. Combined data from two phase III trials of the NK-1 antagonist aprepitant plus a 5HT3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response. Support Care Cancer. 2006;14:354–360.
   PubMed Web of Science ®Google Scholar
• Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol. 2005;23:2822–2830.
   PubMed Web of Science ®Google Scholar
• Navari RM. Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Expert Opin Investig Drugs. 2007;16:1977–1985.
   PubMed Web of Science ®Google Scholar
• Grunberg S, Chua D, Maru A, et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol—EASE. J Clin Oncol. 2011;29:1495–1501.
   PubMed Web of Science ®Google Scholar
• Leal AD, Kadakia KC, Looker S, et al. Fosaprepitant-induced phlebitis: A focus on patients receiving doxorubicin/cyclophosphamide therapy. Support Care Cancer. 2014;22:1313–1317.
   PubMed Web of Science ®Google Scholar
• Drug interactions of aprepitant [slide presentation]. [cited 2015 Nov 9]. Available from: http://www.fda.gov/ohrms/dockets/ac/03/slides/3928s1_03_fda-jarugula.ppt
   Google Scholar
• Scientific discussion: this module reflects the initial scientific discussion for the approval of Emend [cited 2015 Nov 9]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Scientific_Discussion/human/000527/WC500026534.pdf
   Google Scholar
• Aapro MS, Walko CM. Aprepitant: drug-drug interactions in perspective. Ann Oncol. 2010;21:2316–2323.
   PubMed Web of Science ®Google Scholar
• Warr DG, Grunberg SM, Gralla RJ, et al. The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: pooled data from 2 randomised, double-blind, placebo controlled trials. Eur J Cancer. 2005;41:1278–1285.
   PubMed Web of Science ®Google Scholar
• Stiff PJ, Fox-Geiman MP, Kiley K, et al. Prevention of nausea and vomiting associated with stem cell transplant: results of a prospective, randomized trial of aprepitant used with highly emetogenic preparative regimens. Biol Blood Marrow Transplant. 2013;19:49–55.
   PubMed Web of Science ®Google Scholar
• Jordan K, Jahn F, Jahn P, et al. The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination. Bone Marrow Transplant. 2011;46:784–789.
   PubMed Web of Science ®Google Scholar
• Rizzi A, Campi B, Camarda V, et al. In vitro and in vivo pharmacological characterization of the novel NK-1 receptor selective antagonist netupitant. Peptides. 2012;37:86–97.
   PubMed Web of Science ®Google Scholar
• Rossi G, Tilkola SO, Rudengren C, et al. A positron emission tomography study to assess the degree of neurokinin-1 receptor occupancy in the human brain after single doses of netupitant to healthy male subjects [abstract]. J Clin Oncol. 2012;30 Suppl:9054.
   Google Scholar
• Spinelli T, Calcagneli S, Giuliano C. Netupitant PET imaging and ADME studies in humans. J Clin Pharm. 2014;54:97–108.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute Drug Dictionary. [cited 2015 Oct 15]. Available from: http://www.cancer.gov/drugdictionary.
   Google Scholar
• Hesketh PJ, Rossi G, Rizzi G, et al. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol. 2014;25:1340–1346.
   PubMed Web of Science ®Google Scholar
• Aapro M, Rugo H, Rossi G, et al. A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol. 2014;25:1328–1333.
   PubMed Web of Science ®Google Scholar
• Gralla RJ, Bosnjak SM, Hontsa A, et al. A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol. 2014;25:1333–1339.
   PubMed Web of Science ®Google Scholar
• FDA News Release, FDA approves Akynzeo for nausea and vomiting associated with cancer chemotherapy [cited 2015 Nov 9]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements.
   Google Scholar
• Duffy RA, Morgan C, Naylor R, et al. Rolapitant (SCH 619734): a potent, selective and orally active neurokinin NK-1 receptor antagonist with centrally-mediated antiemetic effects in ferrets. Pharmacol Biochem Behav. 2012;102:95–100.
   PubMed Web of Science ®Google Scholar
• Poma A, Christensen J, Pertikis H, et al. Rolapitant and its major metabolite do not affect the pharmacokinetics of midazolam, a sensitive cytochrome P450 3A4 substrate. Support Care Cancer. 2013;21:S154. Abstract 441.
   Google Scholar
• Poma A, Christensen J, Davis J, et al. Phase 1 positron emission tomography (PET) study of the receptor occupancy of rolapitant, a novel NK-1 receptor antagonist. J Clin Oncol. 2014;32:abstr e20690.
   Web of Science ®Google Scholar
• Rapoport B, Chua D, Poma A, et al. Study of rolapitant, a novel, long acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC). Support Care Cancer. 2015;23:3281–3288. doi:10.1007/s00520-015-2738-1.
   PubMed Web of Science ®Google Scholar
• Schwartzberg L, Modiana M, Rapoport B, et al. Safety and efficacy assessment of rolapitant for the prevention of chemotherapy-induced nausea and vomiting following administration of moderately emetogenic chemotherapy in cancer patients in a randomized phase 3 trial. Lancet Oncol. 2015;16:1071–1078.
   Web of Science ®Google Scholar
• Rapoport B, Chasen M, Gridelli C, et al. Safety and efficacy assessment of rolapitant for the prevention of chemotherapy-induced nausea and vomiting following administration of cisplatin-based highly emetogenic chemotherapy in cancer patients in two randomized phase 3 trials. Lancet Oncol. 2015;16:1079–1089.
   PubMed Web of Science ®Google Scholar
• dos Santos LV, Souza FH, Brunetto AT, et al. Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review. J Natl Cancer Inst. 2012;104:1280–1292.
   PubMed Web of Science ®Google Scholar
• Vardy J, Chiew KS, Gallica J, et al. Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer. 1999;94:1011–1015.
   Web of Science ®Google Scholar
• Celio L, Frustaci S, Denaro A, et al. Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multi-center, phase III trial. Support Care Cancer. 2011;19:1217–1225.
   PubMed Web of Science ®Google Scholar
• Aapro M, Fabi A, Nole F, et al. Double-blind, randomized, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol. 2010;21:1083–1088.
   PubMed Web of Science ®Google Scholar
• Fulton B, Goa KL. Olanzapine: a review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs. 1997;53:281–298.
   PubMed Web of Science ®Google Scholar
• Bymaster FP, Calligaro D, Falcone J. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996;14:87–96.
   PubMed Web of Science ®Google Scholar
• Stephenson CME, Pilowsky LS. Psychopharmacology of olanzapine: a review. Brit J Psychiatry. 1999;174:52–58.
   Web of Science ®Google Scholar
• Breitbart W, Tremblay A, Gibson C. An open trial of olanzapine for the treatment of delirium in hospitalized cancer patients. Psychosomatics. 2002;43:175–182.
   PubMed Web of Science ®Google Scholar
• Bymaster FP, Falcone JF, Bauzon D, et al. Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine. Eur J Pharmacol. 2001;430:341–349.
   PubMed Web of Science ®Google Scholar
• Rudd JA, Ngan MP, Wai MK, et al. Anti-emetic activity of ghrelin in ferrets exposed to the cytotoxic anti-cancer agent cisplatin. Neurosci Lett. 2006;392:79–83.
   PubMed Web of Science ®Google Scholar
• Yakabi K, Sadakane C, Noguchi M, et al. Reduced ghrelin secretion in the hypothalamus of rats due to cisplatin-induced anorexia. Endocrinology. 2010;151:3773–3782.
   PubMed Web of Science ®Google Scholar
• Hurren KM, Berlie HD. Lorcaserin: an investigational serotonin 2C agonist for weight loss. Am J Health Syst Pharm. 2011;68:2029–2037.
   PubMed Web of Science ®Google Scholar
• Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry. 2001;62 Suppl 7:22–31.
   PubMed Web of Science ®Google Scholar
• Hale AS. Olanzapine. Br J Hosp Med. 1997;58:443–445.
   Google Scholar
• Goldstein LE, Sporn J, Brown S, et al. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics. 1999;40:438–443.
   PubMed Web of Science ®Google Scholar
• Mizukami N, Yamanchi M, Koike K, et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind placebo-controlled study. J Pain Symptom Manage. 2014;47:542–550.
   PubMed Web of Science ®Google Scholar
• Navari RM, Qin R, Ruddy KJ, et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy: alliance A221301, a randomized, double-blind, placebo-controlled trial. ASCO Palliative Care Symposium; 2015; abstract 176; Boston.
   Google Scholar